SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)

8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024 Company to Host Conference Call and Webcast Today at 9:00 AM ET REDWOOD CITY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- September 26, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Di

Stifel reiterated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

Robert W. Baird reiterated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00

H.C. Wainwright initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $70.00

Robert W. Baird initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00

Piper Sandler initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $93.00

Stifel initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $63.00

Guggenheim resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $40.00

Oppenheimer resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $8.00

REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM ETPresentation Format: Fireside ChatWebcast: https://wsw.com/webcast/guggen2/slno/2028708 Oppenheimer 35th Annual Healthcare Life Sciences ConferencePresentation Date: Tuesday, February 11, 2025 at 2:40 PM ETPresentation Format: Corporate PresentationWebcast: https://wsw.com/webcast/oppenhei

REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. "This financing significantly strengthens our financial position, providing additional support for anticipated commercial launch activities," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno. Under the terms of the agreement with Oxford, Soleno drew an initial $50 million at closing. $100 million will be available in three a

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for

REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. The new Prescription Drug User Fee Act (PDUFA) target action date is March 27, 2025. The FDA determined that responses to recent information requests constituted a major amendment to t

REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Details of the oral presentations are as follows: ESPE 2024 Title:Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in C

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. The FDA Review

REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT A live audio webcast and replay of the Guggenheim and Jefferies events will be availab

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age of 86 years. Dr. Mario served as the Soleno's (formerly Capnia's) Chairman from 2007 through August 2024. "On behalf of the Board of Directors and the entire Soleno family, we extend our deepest condolences to Dr. Mario's family," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. "Dr. Mario's decades-long commitment to the develo

REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA). The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS).  However, the Division's review team will continue to consider the potential need for an advisory committee meeting during thei

REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (dia